Dr. Farrokh Dehdashti, M.D.
Claim this profileWashington University School of Medicine
Area of expertise
Cancer
Farrokh Dehdashti, M.D. has run 4 trials for Cancer.
Breast Cancer
Farrokh Dehdashti, M.D. has run 4 trials for Breast Cancer. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Washington University In St. Louis
Clinical Trials Farrokh Dehdashti, M.D. is currently running
64Cu-LLP2A Imaging
for Blood Cancers
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.
Recruiting
1 award
Phase < 1
4 criteria
Imaging and Abemaciclib
for Breast Cancer
This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy. Abemaciclib is a drug used to treat certain types of hormone receptor positive (HR+), HER2 negative breast cancer. Abemaciclib blocks certain proteins, which may help keep tumor cells from growing. Endocrine therapy adds, blocks, or removes hormones that can cause cancer to grow. FFNP PET imaging is a form of x-ray that uses FFNP as an imaging agent that may provide more precise information about the location of tumors that "light up" with FFNP than a PET scan alone can provide.
Recruiting
1 award
Phase 2
More about Farrokh Dehdashti, M.D.
Clinical Trial Related
4 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Farrokh Dehdashti, M.D. has experience with
- 64Cu-LLP2A
- LS301
- 64Cu-DOTA-ECLIi
- [18F]FluorThanatrace
- Abemaciclib
- 64Cu-DOTA-ECL1i
Breakdown of trials Farrokh Dehdashti, M.D. has run
Cancer
Breast Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Farrokh Dehdashti, M.D. specialize in?
Farrokh Dehdashti, M.D. focuses on Cancer and Breast Cancer. In particular, much of their work with Cancer has involved treating patients, or patients who are undergoing treatment.
Is Farrokh Dehdashti, M.D. currently recruiting for clinical trials?
Yes, Farrokh Dehdashti, M.D. is currently recruiting for 2 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Farrokh Dehdashti, M.D. has studied deeply?
Yes, Farrokh Dehdashti, M.D. has studied treatments such as 64Cu-LLP2A, LS301, 64Cu-DOTA-ECLIi.
What is the best way to schedule an appointment with Farrokh Dehdashti, M.D.?
Apply for one of the trials that Farrokh Dehdashti, M.D. is conducting.
What is the office address of Farrokh Dehdashti, M.D.?
The office of Farrokh Dehdashti, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.